NCT04460001

Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Intravitreal Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

Conditions

• Ophthalmopathy

Interventions

Type	Name	Description
DRUG	Ranibizumab	Intravitreal
DRUG	Ranibizumab	Intravitreal
DRUG	triamcinolone acetate	intravitreal

Timeline

• Start date: 2019-05-16
• Primary completion: 2021-08-01
• Completion: 2021-12-01
• First posted: 2020-07-07
• Last updated: 2020-07-07

Locations

1 site across 1 country: Egypt